Edesa Biotech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Edesa Biotech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $0 | Dec 28, 2021 |
| FY2021 | Sep 30, 2020 | $328.8K | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | $410.9K | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | $211.8K | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | $228.3K | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | $1.27M | Dec 1, 2017 |
| FY2017 | Sep 30, 2015 | $758.7K | Dec 1, 2017 |
| FY2016 | Sep 30, 2014 | $52.8K | Dec 14, 2016 |
| FY2016 | Aug 31, 2014 | $372.1K | Dec 14, 2016 |
| FY2015 | Aug 31, 2013 | $545.5K | Dec 14, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($7.19M) | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | ($6.17M) | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | ($8.37M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($17.55M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($13.34M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($6.36M) | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | ($2.78M) | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | ($5.04M) | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | ($5.03M) | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | ($5.03M) | Dec 1, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($7.91M) | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | ($7.01M) | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | ($9.22M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($18.37M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($23.68M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($6.40M) | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | ($2.83M) | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | ($5.08M) | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | ($5.22M) | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | ($4.91M) | Dec 1, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.67M | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | $2.88M | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | $4.79M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $13.34M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $17.95M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $3.33M | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | $1.10M | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | $2.09M | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | $1.97M | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | $1.73M | Dec 1, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($7.32M) | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | ($4.89M) | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | ($6.64M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($12.28M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($13.66M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($4.99M) | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | ($4.85M) | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | ($4.62M) | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | ($4.70M) | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | ($4.51M) | Dec 1, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | $0 | Dec 15, 2023 |
| FY2023 | Sep 30, 2022 | $5.7K | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $6.1K | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $4.9K | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | $8.1K | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | $382.8K | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | $302.7K | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | $402.3K | Dec 1, 2017 |
| FY2017 | Sep 30, 2015 | $274.6K | Dec 1, 2017 |
| FY2016 | Sep 30, 2014 | $13.5K | Dec 14, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $13.53M | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | $3.81M | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | $8.89M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $11.58M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $14.58M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $10.76M | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | $5.72M | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | $11.78M | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | $7.72M | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | $12.94M | Dec 1, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $1.83M | Dec 13, 2024 |
| FY2024 | Sep 30, 2023 | $1.84M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $2.18M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $1.53M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $1.65M | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | $461.6K | Dec 7, 2020 |
| FY2015 | Sep 30, 2015 | $2.38M | Dec 14, 2015 |
| FY2015 | Sep 30, 2014 | $4.36M | Dec 14, 2015 |
| FY2015 | Aug 31, 2014 | $6.77M | Dec 14, 2015 |
| FY2014 | Aug 31, 2013 | $10.71M | Nov 21, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $12.45M | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | $1.98M | Dec 12, 2025 |
| FY2025 | Sep 30, 2023 | $7.05M | Dec 12, 2025 |
| FY2024 | Sep 30, 2022 | $9.39M | Dec 13, 2024 |
| FY2023 | Sep 30, 2021 | $13.06M | Dec 15, 2023 |
| FY2022 | Sep 30, 2020 | $6.63M | Dec 16, 2022 |
| FY2021 | Sep 30, 2019 | $5.26M | Dec 28, 2021 |
| FY2020 | Dec 31, 2018 | $3.21M | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | $11.29M | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | $7.40M | Nov 30, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($65.91M) | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | ($58.59M) | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | ($52.42M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($44.04M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($26.50M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($13.13M) | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | ($6.73M) | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | ($50.43M) | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | ($45.39M) | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | ($40.36M) | Dec 1, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.80M | Dec 12, 2025 |
| FY2024 | Sep 30, 2024 | $1.00M | Dec 13, 2024 |
| FY2023 | Sep 30, 2023 | $5.40M | Dec 15, 2023 |
| FY2022 | Sep 30, 2022 | $7.09M | Dec 16, 2022 |
| FY2022 | Sep 30, 2021 | $7.84M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $7.21M | Dec 28, 2021 |
| FY2021 | Sep 30, 2019 | $5.03M | Dec 28, 2021 |
| FY2020 | Dec 31, 2018 | $3.37M | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | $4.23M | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | $4.57M | Nov 30, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | (1) | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | (2) | Dec 13, 2024 |
| FY2016 | Sep 30, 2016 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2015 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2014 | 0 | Dec 14, 2016 |
| FY2016 | Aug 31, 2014 | (1) | Dec 14, 2016 |
| FY2015 | Aug 31, 2013 | (2) | Dec 14, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2016 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2015 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2014 | 0 | Dec 14, 2016 |
| FY2016 | Aug 31, 2014 | (1) | Dec 14, 2016 |
| FY2015 | Aug 31, 2013 | (2) | Dec 14, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 7.14M | Dec 12, 2025 |
| FY2025 | Sep 30, 2024 | 3.25M | Dec 12, 2025 |
| FY2024 | Sep 30, 2023 | 3.08M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | 2.38M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | 13.30M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 9.62M | Dec 28, 2021 |
| FY2020 | Sep 30, 2019 | 7.50M | Dec 7, 2020 |
| FY2018 | Sep 30, 2018 | 5.33M | Nov 30, 2018 |
| FY2018 | Sep 30, 2017 | 1.50M | Nov 30, 2018 |
| FY2017 | Sep 30, 2016 | 10.14M | Dec 1, 2017 |